G-BA decisons from 20July 2023
Here are the G-BA decisions from the G-BA meeting held on 20 July 2023 on the early benefit assessments of Enhertu, Imbruvica,
Category: News and updates
G-BA decisions from 12 May 2023
Here are the G-BA decisions from the G-BA meeting held on 12 May 2023 on the early benefit assessments of Tezpire, Adtralza
G-BA decisions from 20 April 2023
Here are the G-BA decisions from the G-BA meeting held on 20 April 2023 on the early benefit assessments of Ultomiris, Genvoya,
The German Ministry of Health introduces new “flat day rates” for hospital day treatments
At the end of September 2022, the hospital commission suggested introducing flat day rates (German: “Tagespauschalen”) for hospital day treatments. Driven by
G-BA requested RWE collection for the second time – Fedratinib in myelofibrosis
Since 2020, the G-BA can request real-world evidence data collection in Germany. However, so far this was only implemented for one product,
New law to stabilise SHI fund finances – Changes to AMNOG are now finalized
On Friday, 21 Oct 2022, the German House of Representatives has now finalized the law on the financial stabilization of statutory health
First study to show that G-DRG system has causal effects on patient care
In September 2022, the University of Hamburg published its study on the effects of the G-DRG system. Hospital treatments in Germany are
Can the expected medical device shortages in Germany be stopped?
Serious medical device shortages in Germany have been observed – and more are expected – as a consequence of the new EU
BfArM tightens data protection requirements for DiGAs – A new certification is needed
Since 2020, clinicians can prescribe – and SHI funds will reimburse – medical apps and digital health treatments, the so-called “DiGAs”. The BfArM assesses these DiGAs
Another cancer drug by Janssen unlikely to be available in Germany
Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,